High Level Working Group discusses chemotherapy treatment for TB
26 November 2013, Moscow, Russian Federation
The High Level Working Group (HLWG) on TB in the Russian Federation met for its 23rd meeting on 26 November 2013. Assistant to the Ministry of Health (MoH), Chief TB Specialist of the MoH and high level representatives from WHO headquarters, WHO/Europe, with the WHO Country Office, the Russian Federation, in collaboration with WHO project staff based in the country took part in the meeting.
The group met to update the national recommendations on TB chemotherapy and to achieve a national consensus on TB treatment principles with focus on the formulation of treatment regimens for M/XDR-TB patients. Along with a Harvard Medical School representative, they also discussed the challenges and next steps for treatment of multidrug-resistant tuberculosis (MDR-TB) in the WHO European Region and specifically, the Russian Federation including:
- treatment of MDR-TB and XDR-TB;
- draft National concept of chemotherapy for tuberculosis in the Russian Federation;
- regional experience in treatment of MDR-TB and XDR-TB and influence of use of rapid TB drug resistance diagnostics on standard treatment regimen outcomes; and
- best practice in designing an effective regimen for MDR-TB and XDR-TB.
Special attention was given to antibiotic resistance as a threat to national security.
With WHO country support in Belarus, the experience of Belarus in treatment of M/XDR-TB and national regulations for use of third line medicines was shared with the HLWG participants as a best practice example. WHO headquarters and Regional Office representatives presented the latest evidence available in the field.